Stockscreener 앱 받기
762.18
1.23%
-9.53
시간 외 거래:
763.00
0.82
+0.11%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly (LLY) at a Crossroads: Assessing the Pullback, Earnings Catalysts, and Long-Term Growth in Diabetes, Obesity, and Alzheimer's - AInvest
Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks
Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool
Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey
Eli Lilly and Company - Lifespan Research Institute
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks
Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest
Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance
Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN
ELI LILLY AND COMPANY (LLY) - MSN
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks
Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance
Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey
Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus
Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma
Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance
Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer? - TipRanks
Eli Lilly’s New Study on SGLT2 Inhibitors: A Potential Game-Changer for CKD Anemia Management - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 20% Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into Indias Weigh-Loss Drug Sector - NDTV Profit
Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer - Insider Monkey
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth - Yahoo Finance
Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom - Yahoo
A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts - Benzinga
Eli Lilly (LLY) Price Target Raised by Guggenheim | LLY Stock Ne - GuruFocus
Guggenheim Adjusts Eli Lilly and Co.'s Price Target to $942 From $936, Keeps Buy Rating - MarketScreener
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly? - Nasdaq
Eli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth - TipRanks
Eli Lilly and Co (India) with Association of Physicians of India announces launch of APIObesity Gurukulstatement - MarketScreener
Eli Lilly and Company (LLY) Stock: US FDA Approves Safer Kisunla Dosing for Early Alzheimer’s - CoinCentral
Eli Lilly’s Shares Sink on Investor Concerns About CVS Move - MSN
Eli Lilly’s Promising Pediatric Study: Mirikizumab for Ulcerative Colitis and Crohn’s Disease - TipRanks
Eli Lilly (LLY) Receives Price Target Upgrade by Morgan Stanley - GuruFocus
Eli Lilly’s Mirikizumab Study: A Potential Game Changer for Ulcerative Colitis - TipRanks
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold? - Yahoo Finance
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly - The Motley Fool
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
0.40%
2.33%
자본화:
|
볼륨(24시간):